Abstract: Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
July 5, 2016
Assignees:
Ethicon Endo-Surgery, Inc., The General Hospital Corporation
Inventors:
Lee M. Kaplan, Nicholas Stylopoulos, Jason L. Harris, Dwight Henninger, Taylor W. Aronhalt, James W. Voegele
Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a novel human embryo co-culture system to improve human embryo growth in vitro and, consequently, increase pregnancy rates in infertile women undergoing in vitro fertilization (IVF) treatment. More particularly, the present invention relates to a method of growing an embryo to a blastocyst stage of development comprising the step of coculturing said embryo in the presence of a population of cumulus cells.
Type:
Grant
Filed:
November 5, 2014
Date of Patent:
June 14, 2016
Assignees:
Institut National de la Santa et de la Recherche Medicale (INSERM), Université Montpellier 1, Centre Hospitalier Universitaire de Montpellier
Abstract: Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.
Type:
Grant
Filed:
June 16, 2011
Date of Patent:
May 17, 2016
Assignees:
North Carolina State University, Northwestern University
Inventors:
Todd R. Klaenhammer, Erika Pfeiler, Mansour Mohamadzadeh
Abstract: The present invention provides conjugates of DNA and cells by linking the DNA to a native functional group on the cell surface. The cells can be without cell walls or can have cell walls. The modified cells can be linked to a substrate surface and used in assay or bioreactors.
Type:
Grant
Filed:
April 8, 2010
Date of Patent:
May 3, 2016
Assignee:
The Regents of the University of California
Inventors:
Shih-Chia Hsiao, Matthew B. Francis, Carolyn Bertozzi, Richard Mathies, Ravi Chandra, Erik Douglas, Amy Twite, Nicholas Toriello, Hiroaki Onoe
Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
April 26, 2016
Assignee:
ORBUSNEICH MEDICAL, INC.
Inventors:
Robert J. Cottone, Jr., Margaret Yoklavich, Sherry Parker
Abstract: Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.
Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
Abstract: The present disclosure relates to a method of assessing a subject's susceptibility to a vascular disease. The method may comprise providing a concentrated population of extracellular vesicles contained in a biological material obtained from a subject, processing the concentrated population to determine if the concentrated population contains a 16S rRNA sequence of Staphylococcus, and upon determining that the concentrated population contains a 16S rRNA sequence of Staphylococcus, further determining that the subject is potentially susceptible to a vascular disease.
Type:
Grant
Filed:
January 9, 2015
Date of Patent:
March 1, 2016
Assignee:
YUNGJIN PHARM. CO., LTD.
Inventors:
Yong Song Gho, Yoon Keun Kim, Eun Young Lee, Sung Wook Hong, Ji Hyun Kim, Seng Jin Choi
Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.
Type:
Grant
Filed:
August 19, 2011
Date of Patent:
March 1, 2016
Inventors:
Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Zimmermann, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
Abstract: Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
Abstract: The present invention provides compositions and methods for transforming primary mammalian cells using an oncogenic form of ALK wherein the transformed cells display features of that of a corresponding tumor cell isolated from a cancer subject. The invention also provides a method for immortalizing normal CD4+ T lymphocytes with a lymphoma-characteristic form of ALK such as NPM-ALK.
Type:
Grant
Filed:
March 5, 2014
Date of Patent:
February 9, 2016
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Mariusz Wasik, James L. Riley, Qian Zhang, Fang Wei
Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS.
Abstract: An implant system and a method for controlling the natural and artificial microenvironments surrounding an implanted device using an artificial tissue system (ATS) and includes methods of diagnostic and testing related thereto. The ATS, among other things, induce better integration, function, and extended lifespan of the devices at the site of implantation. The ATS includes cells, such as naturally occurring, engineered, and/or artificial cells; matrices such as natural, engineered, artificial and/or hybrid matrices; tissue response modifiers (TRM); and/or cell response modifiers (CRM). The specific composition of the ATS is based on the nature of the tissue in which ATS-device combination is implanted and the nature of the implant device, as well as the required function and lifespan of the implanted device. Additionally, the ATS, as well as ATS-device combinations can be utilized in vitro to aid in the design of improved ATS, devices and ATS-device combinations for in vivo uses.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
February 2, 2016
Assignee:
University of Connecticut
Inventors:
Ulrike W Klueh, David I Dorsky, Donald L Kreutzer
Abstract: An object of this invention is to provide a method, etc., for efficiently proliferating a pluripotent epithelial somatic stem cell. A method for producing an epithelial somatic stem cell comprising Steps (A) and (B) below: (A) expressing a gene of a protein having an activity for causing a cell in G0 phase or G1 phase to enter S phase, in a cell population including an epithelial somatic stem cell; and (B) culturing the cell obtained in Step (A) in the presence of an extracellular growth factor.
Abstract: A method for reducing arrhythmic risk associated with cardiomyopathy includes administering a composition containing NAD+ or a mitochondrial targeted antioxidant to an individual in need thereof.
Type:
Grant
Filed:
July 18, 2012
Date of Patent:
December 29, 2015
Assignees:
U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
Abstract: A method for reducing arrhythmic risk associated with cardiomyopathy by improving conduction velocity, includes administering a composition containing NAD+ or a mitochondrial targeted antioxidant to an individual or person in need thereof.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
December 15, 2015
Assignees:
U.S. DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIV. OF ILLINOIS
Abstract: Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous system.
Abstract: The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.
Type:
Grant
Filed:
November 8, 2013
Date of Patent:
December 1, 2015
Assignees:
University of Washington Through its Center for Commercialization, University of Florida Research Foundation, Incorporated, Medical College of Wisconsin
Inventors:
Jay Neitz, Maureen Neitz, James A. Kuchenbecker, William W. Hauswirth
Abstract: The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (Epo), Epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the Epo-producing cells.